While the exact extent to which different defects lead to CA across melanoma subtypes remain to be elucidated, these studies implicate yet another driver mutation - loss of CDKN2 – in aneuploid disease and implicate CA with high-risk uveal melanoma disease. This evidence concerns the gene CDKN2A and melanoma.